Publications by authors named "Geoffrey Chong"

Claim this Profile
I
Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.
Yang Wang, Geoffrey Chong

Crit Rev Oncol Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.
Kimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, Fiona Swain, Ahmad Zargari, Geoffrey Chong

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL.
Rachel M Koldej, Allison Barraclough, Huw Morgan, Sze Ting Lee, Nicholas Holzwart, Geoffrey Chong

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.
Eliza A Hawkes, Jodie B Palmer, Richard Khor, Sze Ting Lee, Melinda Burgess, Geoffrey Chong

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.
Benoit Tessoulin, James Harnett, Seok-Goo Cho, Michał Taszner, Tae Min Kim, Geoffrey Chong

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Utility of Quantitative PET Parameters on Baseline and Interim FDG-PET Scans in Hodgkin Lymphoma.
Natalia Kovaleva, Shin Hnin Wai, Niamh Waters, Sze-Ting Lee, Andrew Carey, Geoffrey Chong

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.
Eliza Chung, Luke Wang, Cameron Wellard, Allison Barraclough, Belinda A Campbell, Geoffrey Chong

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunistic bone density assessment using pretreatment [F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.
Genevieve Douglas, Kane M Nicholls, Erin Paul, Zoe Loh, Sze-Ting Lee, Geoffrey Chong

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review.
Luke Wang, Eliza Chung, Cameron Wellard, Allison Barraclough, Belinda A Campbell, Geoffrey Chong

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma.
Genevieve Douglas, Zoe Loh, Evonne S Y Shum, Sze-Ting Lee, Niamh Waters, Geoffrey Chong

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.
Matthew Loft, Vanessa Wong, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Geoffrey Chong

Intern Med J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of semiquantitative PET features and end-of-therapy PET in grade 3B follicular lymphoma.
Allison Barraclough, Sze Ting Lee, Diego Villa, Greg Hapgood, Don Wilson, Geoffrey Chong

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
Diva Baggio, Eliza Chung, Cameron Wellard, Neil Waters, Tania Cushion, Geoffrey Chong

Intern Med J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Briony Shaw, Eliza Chung, Cameron Wellard, Edward Yoo, Rory Bennett, Geoffrey Chong

EJHaem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma.
Shin Hnin Wai, Sze Ting Lee, Edward R Scheffer Cliff, Michael Bei, Jiwoo Lee, Geoffrey Chong

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Georg Lenz, Eliza Hawkes, Gregor Verhoef, Corinne Haioun, Soon Thye Lim, Geoffrey Chong

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith

Leukemia· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Diva Baggio, Cameron Wellard, Eliza Chung, Dipti Talaulikar, Colm Keane, Geoffrey Chong

Leuk Lymphoma· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Joel Wight, Shin Hnin Wai, Edward Shen, Sze-Ting Lee, Salvatore Berlangieri, Geoffrey Chong

Eur J Haematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong

J Hematol Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
Zoe Loh, Ross Salvaris, Geoffrey Chong, Leonid Churilov, Kate Manos

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic.
Zoe Loh, Eliza A Hawkes, Fiona Chionh, Arun Azad, Geoffrey Chong

Clin Lymphoma Myeloma Leuk· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Georg Lenz, Eliza Hawkes, Gregor Verhoef, Corinne Haioun, Soon Thye Lim, Geoffrey Chong

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis